Novogenia AG (7V0.DE) stock: key figures, P/E, revenue and dividend
Health Care · Germany · ISIN DE000A3C35W0
Novogenia AG financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 25.29 m EUR | 54.30 m EUR |
| Gross profit | 12.39 m EUR | 18.38 m EUR |
| Operating income | 26.37 m EUR | -10.78 m EUR |
| EBIT | 27.40 m EUR | 2.59 m EUR |
| Net income | 18.46 m EUR | 545,465.07 EUR |
| Diluted EPS – continuing operations | 6.15 EUR | 0.05 EUR |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Novogenia AG
Novogenia AG manufactures and sells personalized health products in global markets. The company offers products, such as personalized supplements and cosmetics; and services, including genetic testing, advanced therapies like personalized infusion therapies and reproductive genetics, and contract manufacturing. The company was formerly known as Darwin AG and changed its name to Novogenia AG in June 2026. The company was incorporated in 2021 and is based in Munich, Germany.
More stocks
- Seritage Growth Properties (SRG)
- Shihlin Development Company Limited (5324.TWO)
- Hites S.A. (HITES.SN)
- Here Group Limited (HERE)
- Tropical Canning (Thailand) Public Company Limited (TC.BK)
- Kumkang Kind (014280.KS)
- Chitec Technology Co., Ltd. (3430.TWO)
- CTW Cayman Class A Ordinary Shares (CTW)
- Pharol SGPS SA (PHR.LS)
- Rayence Co. Ltd (228850.KQ)
- SUNHYDROGEN, INC. (HYSR)
- Taitien Electronics Co Ltd (8289.TWO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.